The interim JODR arose from a commitment made by Premiers in fall 2006 to address the current “patchwork” of access to oncology drugs, where access is dependent on where one lives, leading to confusion by patients. The objective of the interim JODR is to build the foundation for a streamlined national oncology drug review process that will lead to more consistent decision-making – and ultimately access to a more consistent standard of care – as well as improved clarity for patients, health professionals and industry about how, when and why decisions are made.
The principles outlined below support this overarching objective. They were first discussed at a July 2007 meeting of the JODR Advisory Committee and revised at subsequent Advisory Committee meetings and in consultation with key stakeholders, most notably the patient advocacy community. The principles are aligned with the objectives of Memorandum of Understanding (MOU) creating the interim JODR (P/T oncology collaborative) and are intended to provide a foundation for guiding the interim process, which will culminate in recommendations to P/T Deputy Ministers on a permanent national oncology drug review process.
A review process with governance structures which are fair, objective, transparent and accountable to patients, payers and the public.
Cancer treatment drugs are evaluated within a review process and decision making framework that are consistent with those used for drugs for other diseases.
A review process that is multidisciplinary, cross-jurisdictional and collaborative in nature with appropriate input from key stakeholders and linked to other key national initiatives.
A review process that reflects an ongoing commitment to excellence through incorporation of best practices in a spirit of continuous quality improvement.
A review process with capacity for rigorous and consistent evidence-based clinical and pharmacoeconomic reviews to support evidence-based decision-making.
A review process that includes an ethical framework.
A review process that is cost-efficient, effective and streamlined (i.e. reduced duplication) to support timely decision-making.
A review process with capacity for data capture and ongoing evaluation (decision monitoring/ performance measurement) to support continuous process improvements. In addition, capacity for health outcomes and economic impact analysis to support decision-making and planning.
Get the PDF version of the myeloma handbook by clicking here...
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors:
Ortho Biotech Celgene The Binding Site Amgen
